OMER · Omeros Corporation
$16.57
-1.72% last session
End-of-day data · close of 2026-10-23
Market cap
$1B
Enterprise value
$1B
Trailing P/E
13.6
Forward P/E
13.5
Dividend yield
0.0%
Beta
2.57
Avg volume
2M
Employees
0K
Daily Change %
-1.72%
5 Days Change
1.35%
10 Days Change
-10.09%
30 Days Change
-17.69%
60 Days Change
-14.06%
Month to Day Change
-10.29%
Year to Day Change
-3.55%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — OMER
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-14
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-14 | Cantor Fitzgerald | Reiterates | Overweight | $22.00 |
| 2026-09-22 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | $0.00 → $22.00 |
| 2026-06-26 | HC Wainwright & Co. | Maintains | Buy | $40.00 → $33.00 |
| 2026-06-10 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-05-14 | HC Wainwright & Co. | Reiterates | Buy | $40.00 |
| 2026-04-21 | D. Boral Capital | Maintains | Buy | $36.00 |
| 2026-01-27 | D. Boral Capital | Maintains | Buy | $36.00 |
| 2026-01-08 | HC Wainwright & Co. | Maintains | Buy | $20.00 → $40.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- neutral: RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- bearish: Price vs 50-day MA: Trading 10.5% below the 50-day MA ($18.52).
- bullish: Price vs 200-day MA: Trading 24.0% above the 200-day MA ($13.36).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.33) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($6.28) and high ($21.05).
OMER Price Chart
Loading chart for OMER…
Fundamentals
About Omeros Corporation
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$133B 18.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 6.5% YTD
MRNA
Moderna, Inc.
$80B 587.1% YTD
ARGX
argenx SE
$55B 4.1% YTD
ONC
BeOne Medicines Ltd.
$43B 25.8% YTD
RVMD
Revolution Medicines, Inc.
$40B 135.6% YTD
RPRX
Royalty Pharma plc
$37B 67.3% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.